Encapsulating Peritoneal Sclerosis: Prevention and Treatment

@article{Kawanishi2007EncapsulatingPS,
  title={Encapsulating Peritoneal Sclerosis: Prevention and Treatment},
  author={Hideki Kawanishi and Misaki Moriishi},
  journal={Peritoneal Dialysis International},
  year={2007},
  volume={27},
  pages={289 - 292}
}
Since the first peritoneal dialysis (PD) patients with encapsulating peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered primarily a fatal complication. The incidence of EPS in PD patients has been reported to be 2.5%, with a negative effect of increasing PD duration (which also augments mortality). Because EPS occurs after withdrawal from PD in more than half of all cases, strict monitoring is necessary when a long-term PD patient is withdrawn from PD. Maintaining… 

Figures from this paper

Encapsulating peritoneal sclerosis: The abdominal cocoon

Three cases of EPS in patients on PD with different presentation of EPS are reported, their treatment and a brief literature review are reported.

Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment.

A diagnostic and a therapeutic algorithm for EPS are presented based on the best available published data and the combined experience, with a focus on treatment.

Surgical treatment of post-transplant encapsulating peritoneal sclerosis: A single-center experience.

It can be especially devastating for patients with a long-term PD history to have EPS after a successful transplant, and its management should be done in experienced clinics to decrease its mortality and morbidity rates.

Encapsulating peritoneal sclerosis.

  • M. CisseD. Dia B. Diouf
  • Medicine
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • 2013
A case of EPS is reported in a 40-year-old man who was switched to hemodialysis because of peritoneal tuberculosis after 2 years of PD, and anti-tuberculosis treatment associated with a low dose of corticosteroids stabilized the disease.

mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience

Adopting an immunosuppressive protocol based on mTORi, mycophenolate mofetil and steroids in order to prevent PostTx-EPS in transplanted patients at high risk is suggested.

Additive Effectiveness of Everolimus Plus Tamoxifen Therapy in Treatment of Encapsulating Peritoneal Sclerosis

A case of EPS who improved with everolimus plus tamoxifen therapy is presented, the most severe form of sclerosing peritonitis and there is no proven effective therapy for EPS.

Encapsulating Peritoneal Sclerosis (EPS): Analysis of Current Knowledge in the Literature and Observation of a Suspect Case

An overview of the current literature available and a “suspect” case of a 59-year-old male patient who underwent a single kidney transplant after a period of 8 year of peritoneal dialysis with numerous sub occlusive episodes, some of them required hospitalizations in a period between 2011 and 2019 are discussed.

Encapsulating Peritoneal Sclerosis in a Peritoneal Dialysis Patient with Prune-Belly Syndrome: a Case Report

This case of prune-belly syndrome has all the necessary elements for the development of EPS, and it is felt that it should be reported as the peroperative diagnosis was unexpected.

Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death

  • M. LambieL. Teece S. Davies
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2019
EPS risk estimates are lower when calculated using competing risk of death analyses, and a patient’s estimated risk of EPS is country-specific and can be predicted using age, primary renal disease and duration of PD.

Development of Encapsulating Peritoneal Sclerosis in Kidney Allograft Recipients: Risk Factors and Clinical Implications

PD duration and the number of peritonitis attacks were the statistically significant risk factors for development of bowel obstruction due to EPS in post-transplant period.

References

SHOWING 1-10 OF 17 REFERENCES

Treatment options for encapsulating peritoneal sclerosis based on progressive stage.

EPS is not an incurable disease and can be completely overcome by active diagnosis and treatment, and Methylprednisolone pulse therapy is recommended during the early stage.

Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study.

It appears that PD can be continued successfully with an acceptable, low risk for EPS for at least 8 years, whereas stricter caution is required for patients receiving PD for longer periods.

Risk factors and preventive measures for encapsulating peritoneal sclerosis--Jikei experience 2002.

Based on the observational results regarding the risk of EPS development and the characteristic features of patients with EPS, a withdrawal protocol for long-term CAPD patients is established, with the goal of preventing EPS.

Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis.

It is suggested that periodic abdominal irrigation through theperitoneal catheter preserved after PD enhances the recovery of peritoneal damage and is a useful marker of viability and proliferation of PMCs.

Sclerosing peritonitis: the experience in Australia.

  • R. RigbyC. Hawley
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1998
Severe sclerosing peritonitis is a serious complication of peritoneal dialysis and there is a time dependent increase on CAPD.

Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.

It is the recommendation of the authors that EPS be adopted as the more appropriate term for encapsulating peritoneal sclerosis, and the best literal definition of EPS is based on clinical-pathologic criteria.

Encapsulating Peritoneal Sclerosis: Definition, Etiology, Diagnosis, and Treatment

The most common term used in the nephrology literature in recent years has been sclerosing encapsulating peritonitis, but the popularity of the term does not necessarily validate its continued use, as it is marred by its morphologic inaccuracy.

Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery.

It is suggested that peritoneal microvascular hyperplasia is a factor involved in recurrence, and that patients with recurrence may have an irreversible pathologic condition and may experience repeated recurrences.

Immunosuppression in sclerosing peritonitis.

  • B. JunorM. Mcmillan
  • Medicine
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis
  • 1993
Longer survival of patients given immunosuppressive therapy with or without a functioning transplant in sclerosing peritonitis is reported, and experience suggests that Immunosuppression is beneficial in ScP.